This study evaluates the efficacy of netarsudil 0.02% ophthalmic solution in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Aerie Pharmaceuticals’ fixed-dose combination of netarsudil and latanoprost has been cleared by the FDA.

Weekly case challenge

Investigators evaluated the 2-year efficacy and safety of cataract surgery with the Hydrus microstent (Ivantis) implantation.

Investigators assessed whether iStent implantation during cataract surgery was associated with a greater reduction in ocular antihypertensive medication usage compared with cataract surgery alone.

This study assessed the association between serum levels of complement component 3 (C3) and primary open-angle glaucoma (POAG) severity.

This lecture from AGS 2018 a panel discusses how best to handle the case of a 73-year-old patient with open-angle glaucoma that is fairly stable, his pressure has been reduced with medication 20%-25% from baseline, a reliable visual field taker, and OCT scans show thinning in each eye.

The FDA has approved the use of the Hydrus microstent in conjunction with cataract surgery to reduce IOP in patients with mild to moderate primary open-angle glaucoma.

Investigators evaluated the safety and efficacy of the CyPass supraciliary microstent in patients with refractory open-angle glaucoma.